Regulatory rejection flurry does not make a storm
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Upcoming events – binary outcomes for Inflarx and Achieve
Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
Upcoming events – Achillion fishes for complements as Aquestive tackles ALS
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.